- Checkmate Pharmaceuticals, Inc. is a small clinical-stage biotech focused on the immune-system-based therapeutic development for combating cancer, particularly targeting TLR9 of pDCs with virus-like delivery.
- Checkmate Pharmaceuticals currently has one therapeutic in their pipeline known as Vidutolimod ("CMP-001"), a CPG-A TLR9 agonist, being tested in multiple clinical trials for various indications including HNSCC and Melanoma.
- Checkmate is in a fair financial position with funding for ~1-2 years at a 2020 cash burn of -$38M and an expected doubling in 2021, albeit still non-revenue producing till 2023-24.
- Checkmate has several upcoming catalysts from 2021-2022 with the earliest being the critical preliminary HNSCC data, which should be carefully monitored for safety issues.
- In summary, the author projects Checkmate Pharmaceuticals, Inc. as a "buy" at a 5-year price target of $39 (+427% upside).
For further details see:
Checkmate: Promising pDC Therapeutic Holds Triple-Digit Upside In Melanoma